论文部分内容阅读
2型糖尿病是大血管和微血管疾病主要的危险因素。大约35%的2型糖尿病患者会发生肾脏病,导致死亡率升高。强化降糖策略已被证明能够在2型糖尿病患者中减少肾脏并发症的替代标记物,但其改善晚期肾脏并发症的证据迄今十分有限。尽管使用了优化血糖控制和单药阻断肾素-血管紧张素-醛固酮系统(RAAS),2型糖尿病患者的死亡风险和心肾并发症仍然在增加。依帕列净,是选择性钠-葡萄糖协同转运蛋白2的一种抑制剂,能够降低肾脏重吸收葡萄糖、增加尿葡萄糖排泄,从而减轻
Type 2 diabetes is a major risk factor for macrovascular and microvascular disease. About 35% of people with type 2 diabetes develop kidney disease, leading to an increase in mortality. Intensive glucose-lowering strategies have proven to be a surrogate marker for reducing renal complications in patients with type 2 diabetes, but their evidence for improving advanced renal complications has so far been limited. Despite the use of optimized glycemic control and the monotherapy block renin-angiotensin-aldosterone system (RAAS), the risk of death and heart-kidney complications in patients with type 2 diabetes are still on the rise. Empagliflozin, an inhibitor of selective sodium-glucose cotransporter 2, reduces renal reabsorption of glucose and increases urinary glucose excretion thereby reducing